161 related articles for article (PubMed ID: 35835035)
21. Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.
Huang X; Li Y; Feng H; Chen P; Liu W
Front Neurol; 2018; 9():77. PubMed ID: 29535672
[TBL] [Abstract][Full Text] [Related]
22. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
Roda RH; Doherty L; Corse AM
Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in late-onset myasthenia gravis is safe and effective.
Sahai SK; Maghzi AH; Lewis RA
Muscle Nerve; 2020 Sep; 62(3):377-380. PubMed ID: 32239711
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
Jonsson DI; Pirskanen R; Piehl F
Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
Koul R; Al Futaisi A; Abdwani R
Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis.
Ren J; Wang J; Liu R; Jin Y; Guo J; Yao Y; Luo J; Hao H; Gao F
Eur Neurol; 2023; 86(6):387-394. PubMed ID: 37778340
[TBL] [Abstract][Full Text] [Related]
27. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.
Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O
Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209
[TBL] [Abstract][Full Text] [Related]
28. Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old.
Doughty CT; Suh J; David WS; Amato AA; Guidon AC
Muscle Nerve; 2021 Dec; 64(6):651-656. PubMed ID: 34378210
[TBL] [Abstract][Full Text] [Related]
29. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of thoracoscopic thymectomy in the treatment of juvenile myasthenia gravis.
Christison-Lagay E; Dharia B; Vajsar J; Kim PC
Pediatr Surg Int; 2013 Jun; 29(6):583-6. PubMed ID: 23423693
[TBL] [Abstract][Full Text] [Related]
31. Incidence and Ocular Features of Pediatric Myasthenias.
Mansukhani SA; Bothun ED; Diehl NN; Mohney BG
Am J Ophthalmol; 2019 Apr; 200():242-249. PubMed ID: 30653958
[TBL] [Abstract][Full Text] [Related]
32. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
33. Serial Stimulated Jitter Analysis In Juvenile Myasthenia Gravis.
Bhatia S; Quinlan H; McCracken C; Price EW; Guglani L; Verma S
Muscle Nerve; 2018 Nov; 58(5):729-732. PubMed ID: 30106469
[TBL] [Abstract][Full Text] [Related]
34. Myasthenia gravis in childhood.
Anlar B; Ozdirim E; Renda Y; Yalaz K; Aysun S; Topçu M; Topaloğlu H
Acta Paediatr; 1996 Jul; 85(7):838-42. PubMed ID: 8819551
[TBL] [Abstract][Full Text] [Related]
35. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
[TBL] [Abstract][Full Text] [Related]
36. Open versus thoracoscopic thymectomy for juvenile myasthenia gravis.
Derderian SC; Potter DD; Bansal S; Rowse PG; Partrick DA
J Pediatr Surg; 2020 Sep; 55(9):1850-1853. PubMed ID: 31826816
[TBL] [Abstract][Full Text] [Related]
37. Outcome and clinical features in juvenile myasthenia gravis: A systematic review and meta-analysis.
Lin Y; Kuang Q; Li H; Liang B; Lu J; Jiang Q; Yang X
Front Neurol; 2023; 14():1119294. PubMed ID: 36970540
[TBL] [Abstract][Full Text] [Related]
38. Thoracoscopic thymectomy for juvenile myasthenia gravis.
Kim AG; Upah SA; Brandsema JF; Yum SW; Blinman TA
Pediatr Surg Int; 2019 May; 35(5):603-610. PubMed ID: 30729982
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in Myasthenia Gravis - Where do we stand?
Siddiqi ZA; Khan W; Hussain FS
Expert Opin Biol Ther; 2021 Aug; 21(8):1013-1023. PubMed ID: 33566716
[No Abstract] [Full Text] [Related]
40. Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar.
Fatehi F; Moradi K; Okhovat AA; Shojatalab G; Sedighi B; Boostani R; Sarraf P; Haghi Ashtiani B; Ghasemi M; Moussavi S; Anjidani N; Nafissi S
Front Neurol; 2021; 12():682622. PubMed ID: 34512504
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
